SinoMab Bioscience - About the company
SinoMab Bioscience is a public company based in Hong Kong (China), founded in 2001. It operates as a Therapeutic antibodies for the treatment of cancer and autoimmune diseases.. SinoMab Bioscience has raised an undisclosed amount in funding from CICC and Apricot Capital. The company has 3655 active competitors, including 1260 funded and 865 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Biogen.
Company Details
SinoMab BioScience, a clinical stage biopharmaceutical company, is discovering and developing therapeutic antibodies for the treatment of cancer and autoimmune diseases. The company claims that they have a full spectrum of drug development capabilities covering antibody re-engineering, cell line development, bioprocessing, production and preclinical studies that are essential for bringing our lead candidates through clinical development. The company drug pipeline includes antibody candidates for non-Hodgkin’s Lymphoma, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Key Metrics
Founded Year
2001
Location
Hong Kong, China
Stage
Public
Latest Funding Round
Ranked
1474th among 3655 active competitors
Employee Count
38 as on Apr 30, 2026
Similar Companies
Exit Details
Public
SinoMab Bioscience's IPO details
SinoMab Bioscience got listed on Nov 12, 2019.
Click here to take a look at SinoMab Bioscience's IPO in detail
Sign up to download SinoMab Bioscience's company profile
SinoMab Bioscience's funding and investors
SinoMab Bioscience has raised funding over 1 round. Its latest funding round was a PE round on Feb 20, 2019 for $*****. 2 investors participated in its latest round. SinoMab Bioscience has 2 institutional investors.
Here is the list of recent funding rounds of SinoMab Bioscience:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Feb 20, 2019 | 2639241 | PE | 2435729 | 7204077 | 8660431 | 8600394 |
Access funding benchmarks and valuations. Sign up today!View details of SinoMab Bioscience's funding rounds and investors
SinoMab Bioscience's founders and board of directors
Founder? Claim ProfileSinoMab Bioscience's employee count trend
SinoMab Bioscience has 38 employees as of Apr 26. Here is SinoMab Bioscience's employee count trend over the years:
Uncover SinoMab Bioscience's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
SinoMab Bioscience's Competitors and alternates
Top competitors of SinoMab Bioscience include Jazz Pharmaceuticals, BeiGene and Biogen. Here is the list of Top 10 competitors of SinoMab Bioscience, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd |  Biogen 1978, Cambridge (United States), Public | Developer of therapies for neurodegenerative and immunology disorders | $80M | 78/100 | |
4th | PTC Therapeutics 1998, South Plainfield (United States), Public | Developer of small molecule drugs for the treatment of rare diseases | $248M | 77/100 | |
5th |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating human disease conditions | $821M | 75/100 | |
6th | Blueprint Medicines 2008, Cambridge (United States), Acquired | Developer of selective kinase inhibitors for patients with genomically defined cancers | $115M | 72/100 | |
7th | Senti Biosciences 2016, San Francisco (United States), Public | Developer of cell-based therapies for cancer treatment | $158M | 72/100 | |
8th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 72/100 | |
9th | _1548135965397.png?devicePixelRatio=2&height=30&width=30){kind=logo} Kronos Bio 2017, San Mateo (United States), Acquired | Developer of small molecule based therapeutics for cancer treatment | $271M | 72/100 | |
10th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
1474th | SinoMab Bioscience 2001, Hong Kong (China), Public | Therapeutic antibodies for the treatment of cancer and autoimmune diseases. | - | 37/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on SinoMab Bioscience's competitors? Click here to see the top ones
SinoMab Bioscience's Investments and acquisitions
SinoMab Bioscience has made no investments or acquisitions yet.
News related to SinoMab Bioscience
Filter this list•
•
•
•
SinoMab's IND Application of SM17 has once again Received Approval from NAMPACN Newswire•Sep 12, 2023•SinoMab Bioscience
•
•
•
•
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about SinoMab Bioscience
Explore our recently published companies
- MGI Software - San Francisco based, Funding Raised company
- Bill Orbit - Noida based, 2023 founded, Unfunded company
- Docket Care - Lucknow based, 1993 founded, Unfunded company
- Swisscast SA - Switzerland based, 2020 founded, Unfunded company
- Arrcadia Leisure Journey - Chandigarh based, 2012 founded, Unfunded company
- Stallion Institute of International Studies - Chandigarh based, 2015 founded, Unfunded company
